Jun 25 2019
MSCO and Kiang Wu Hospital Oncology Image Seminar was held on 2019-5-18 at Macau. Attendance came form China mainland, HK, Taiwan and Macau. There were 4 sections in the seminar, focus on prostate cancer, breast cancer, lung cancer and lymphoma. In each section, speakers talks about recent progress in disease specific image characteristics, advance in […]
Jun 25 2019
Nature 2019 May; 569(7756) Immunotherapy combined with PD-1 and CTLA-4 is effective for renal melanoma and non-small cell lung cancer.However, thiscomes at the cost of frequent, serious immune-related adverseevents, necessitating a reduction in the recommended dose ofipilimumab that is given to patients. Immune-related adverse events that result from therapy with checkpoint inhibitors are usually satisfactorily treated […]
Jun 25 2019
Lee Schwartzberg,Beata Korytowsky,John R. Penrod,Ying Zhang, T. Kim Le,Cory Batenchuk, Lee Kru Lung cancer is the first most common malignancy in the wild word, and the leading cause of cancer-related mortality. Approximately 85% of lung cancers are non-small-cell lung cancer (NSCLC). More than half of all lung cancers in the United States are diagnosed at […]
Apr 11 2019
On December 8, 2019. MSCO held a MTD meeting with team for 6th Affiliated hospital of Sun Yet-sen university (Guangzhou), 5th Affiliated hospital of Sun Yet-sen university (Zhuhai) and Cancer centre of Sun Yet-sen university (Guangzhou). Several cases were discussed in the meeting, regard the treatment sequence of chemo and operation procedure. Use of IO […]
Apr 11 2019
On March 23, MSCO held a conference on Immuno- Oncology in MGM. Experts from China and Macau were joined and shared their opinions on this hot topic. Two IO drugs has been licensed in China and patients can get assess to IO treatment more easily than before. However many issues were now became more and […]
Apr 11 2019
Non-small cell lung cancer (NSCLC) is the predominant histological type of lung cancer and is characterized by the highest mortality and incidence rates among these types of malignancies (1, 2). Traditional Chinese medicine (TCM) has been applied for centuries in China (3, 4). Cardiac glycosides, a class of natural products, have been identified as a […]
Dec 22 2018
2018 Member meeting of MSCO was held on Sep 29, 2018. During this meeting many important issues were voted for approve, regarding financial and regulations on management.
Dec 22 2018
This article summaries recent progresses published in high impact journals on lung cancer research and treatment. Kindly provided by Ms. Dandan Hu (胡丹丹), a MSI from Roche China, will continually update for every month. Article in Chinese. LANCET SERIES Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: a retrospective, multicentre, cohort study Lancet Oncol; Published […]
Dec 17 2018
The 2018 Annual Scientific Symposium of MSCO was successfuly held on September 29, 2018 at Mandarin Oriental Hotel, Macau. Invited speaker including Dr. Tongyu Li from Sun Yat-sen University Cancer Center, Dr, Ding Yu and Dr. Huijing Wu from Hubei Cancer Center, Dr. Yizhun Zhu, Prof. Elaine,Leung from MUST, Dr. Xingxiang Pu from Hunan Cancer […]
Jul 1 2020
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen, Alexander C. Huang, et al. Published at Nature on 08 August 2018 Tumor cells evade immune surveillance by upregulating the surface expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1 (PD-1) receptor on T cells to elicit the immune checkpoint response. Anti-PD-1 antibodies have shown remarkable promise in treating tumors, including lung cancer and […]
Read More
By Yabing • Oncology News • 0